PMS7 DETERMINANTS OF TNF INHIBITOR DOSE ESCALATION IN PATIENTS WITH RHEUMATOID ARTHRITIS  by Baser, O et al.
13th Euro Abstracts A303
reported outcomes (PROs) simultaneously following treatment with certolizumab 
pegol (CZP) 200 mg + methotrexate (MTX), in the RAPID 1 and RAPID 2 trials. 
METHODS: The proportions of patients reporting improvements ≥MCID in RAPID 
1 (Week 24 and Week 52) and RAPID 2 (Week 24) were determined for the following 
PROs: arthritis pain (0–100 mm visual analogue scale [VAS], MCID ≥ 10 mm), fatigue 
(Fatigue Assessment Scale, 0–10 numeric rating scale, MCID ≥ 1 point), physical 
function (Health Assessment Questionnaire-Disability Index, MCID ≥ 0.22 points), 
patient’s global assessment of disease activity (PtGA, 0–100 mm VAS, MCID ≥ 
10 mm), and HRQoL (SF-36 physical and mental component summaries [PCS, MCS], 
MCID ≥ 2.5 points). NNT to achieve improvements ≥MCID in at least 1, 2, 3, 4, 5, 
or 6 out of the 6 considered PROs simultaneously with CZP + MTX compared with 
PBO + MTX were also calculated. RAPID 1: NCT00152386; RAPID 2: NCT00160602. 
RESULTS: The NNT to report clinically meaningful improvements in up to 5/6 PROs 
following CZP + MTX treatment was very low; approximately 2–3 additional patients 
after 24 weeks (RAPID 1 and RAPID 2). The NNT remained similar at 52 weeks 
(RAPID 1). The NNT to report improvements in all 6 PROs was 5 additional patients. 
In patients who achieved MCIDs in at least 5 of 6 PROs by Week 52, clinically 
meaningful improvements were more likely to be reported in pain, fatigue, physical 
function and PtGA than SF-36 PCS or particularly MCS. CONCLUSIONS: Patients 
with active RA report meaningful and broad relief in PROs following treatment with 
CZP. The low NNTs indicate that few patients need to be treated with CZP + MTX 
to report relief from the multiple burdens of RA.
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OBJECTIVES: A Provincial prospective observational cohort study observes consecu-
tive Rheumatoid Arthritis (RA) patients starting anti-TNF therapy (inﬂ iximab, etan-
ercept or adalimumab). We aimed to assess the impact of switching anti-TNF agents 
at different time points. METHODS: Data in the registry is collected at baseline, 3 
months, and every 6 months thereafter up to 3 years on patients receiving anti-TNF 
agents. We grouped patients as inﬂ iximab or adalimumab starters, and etanercept 
starters. Health-related quality of life was measured with the EQ-5D and single index 
scores were calculated using US value sets. Clinical outcome measures assessed were 
the HAQ and DAS28 scores. We analyzed the mean EQ-5D index score, the HAQ 
score, and the DAS28 score over time within baseline starter groups according to the 
time of switch of treatment. RESULTS: From 1222 patients in the registry, 649 
patients had 27 months follow-up assessment and 76.7% remained on the ﬁ rst anti-
TNF. For these patients, signiﬁ cant improvement was observed by 3 months in the 
EQ-5D (mean change 0.296, P < 0.001), the HAQ (mean change −0.822, P < 0.001) 
and DAS28 (mean change −2.84 P < 0.001) that was sustained over the follow-up 
period. Those who switched at 3 months (primary failures) had signiﬁ cantly responded 
by the next measurement and the 27 months changes in outcomes were comparable 
to non-switchers (all P < 0.01). Patients who failed the ﬁ rst anti-TNF after the 3-month 
time point (secondary failures) obtained from 50% (HAQ) to 68% (EQ-5D) of the 
mean change compared to non-switchers (P < 0.05). Switching from Inﬂ iximab or 
adalimumab to etanercept or vice versa produced similar outcomes. CONCLUSIONS: 
The results show that primary failures to anti-TNF show similar responses to patients 
responding to their ﬁ rst anti-TNF agent. Secondary failures obtain about two-third of 
the outcomes compares to no-switchers and primary failures. Longer follow up is 
needed to see if the secondary failure patients can sustain the obtained 
improvement.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, progressive, disabling autoim-
mune disease. The ﬁ rst biologic drug (etanercept) for the treatment of RA was regis-
tered in 1998, the latest in 2009 (EMEA). Study design of randomized controlled trials 
(RCT) of RA has changed in the past years, specially in point of reducing the time on 
placebo. Our aim was to compare the efﬁ cacy, safety and tolerability of available 
biologic drugs and to review the challenges of comparing RA studies with different 
structures, taking the example of the lately registered drug certolizumab pegol. 
METHODS: Systematic literature search was performed (closed on 16.08.2009) for 
RCTs with minimum duration of 24 weeks, involving drugs that have been registered 
for the treatment of RA after traditional disease modifying drug failure. Improvement 
of symptoms by 20%, 50% and 70% (deﬁ ned by the American College of Rheumatol-
ogy, ACR), adverse events and withdrawals were considered as endpoints in the 
metaanalysis. RESULTS: Altogether 14 RCTs (adalimumab 3, certolizumab pegol 2, 
etanercept 2, inﬂ iximab 4, tocilizumab 2, golimumab 1) involving 6739 patients were 
selected for the analysis. Efﬁ cacy of certolizumab pegol was superior to other drugs 
at ACR20, 50 and 70 but heterogenity was observed at certain safety endpoints. 
Contrary to previous trials, patients on placebo not achieving ACR20 response at 
week 16 were withrawn in the certolizumab pegol studies. Thus patient number in 
the placebo group decreased dramatically for the remaining 8 weeks. To exclude this 
bias, we compared only the active arms and there was no signiﬁ cant difference in 
terms of safety and tolerability among the drugs. Analysis by patients years conﬁ rmed 
this ﬁ nding. CONCLUSIONS: Effectiveness and safety of recently registered biologic 
drugs in RA are similar to the previous agents. Differences in protocol of former and 
present RCTs should be carefully considered for the analysis.
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OBJECTIVES: Switching among tumor necrosis factor-α inhibitor (TNFi) agents or 
to another biologic is relatively common, but determinants of dose escalation are 
largely unknown. Among individuals who are escalating the dose from their ﬁ rst TNFi, 
we identiﬁ ed factors associated with the choice of dose escalation in a retrospective 
analysis of medical and pharmacy claims and eligibility data. METHODS: Eligible 
patients were ≥18 years of age, diagnosed with rheumatoid arthritis (RA, 2 diagnoses 
≥2 months apart) from January 2003–March 2008, had initiated a new TNFi prescrip-
tion after a 6-month biologic-free period and had at least 6 months of continuous 
enrollment. Kaplan-Meier (KM) analysis and Cox regression were used to analyze 
time to dose escalation. Multinomial logistic regression was used to determine factors 
affecting dose escalation. RESULTS: A total of 11,903 (6.9%) of 173,533 RA patients 
were identiﬁ ed. Among these patients, 16% (n = 1,903) after a mean of 261 days 
escalated their dose. Comorbidity scores, such as the severity index for rheumatoid 
arthritis (SIFRA) and Elixhauser, were higher for patients who escalated their dose. 
The likelihood of escalating the dose was increased by female sex, younger age, and 
baseline use of corticosteroids or cytotoxic agents. Baseline use of methotrexate raised 
the likelihood of dose escalation (relative risk ratio, 1.58). CONCLUSIONS: After 
initiating TNFi treatment, many RA patients failed to remain on therapy and escalated 
doses or switched to a second TNFi or another biologic ~1 year. Factors inﬂ uencing 
whether patients increased their dose included gender, age, and use of certain agents 
at initiation of the TNFi. a limitation of this study is that patients with <6 months of 
TNFi treatment were not included.
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OBJECTIVES: The aim of this study is to evaluate the occurrences of secundary hip 
and femur fractures according to its different risk factors with follow up 8 years. 
METHODS: In this retrospective study the data derive from the ﬁ nancial database of 
the Hungarian National Health Insurance Fund Administration, based on the 10th 
revision of the International Classiﬁ cation of Diseases (ICD) with ICD code S7200. 
The patients included into the study had femur neck fracture and being discharged 
from the hospital after the primary treatment in 2000. The patients with polytrauma 
were excluded from the study. We evaluated data according to sex, age, type of 
fracture, type of surgery, local complications, type of residence. RESULTS: A total of 
3783 patients met selection criteria of primary femoral neck fracture. During the 
postoperative 8 years 347 patents (9,2%) had secondary hip and femur fractures. 
Average age of patient with primary hip fracture 78 years, with secundary hip fracture 
80,6 years. We demonstrated the following incidence rate of secundary hip fractures 
according to risk factors: Sex: female: 10,3%, male: 5,8%. Age groups: 60–69 y: 
5,3%, 70–79 y: 7,5%, 80–89 y: 12,4%, 90 y-: 14,1%. Type of fracture: lateral: 6,9%, 
medial 9,5%. Type of surgery: osteosynthesis: 8,5%, arthroplasty: 13,6%. Local 
complications: yes: 10,6% no: 9%. Type of residence: capital 11,5%, village: 7,9%, 
city: 10%, town: 8,2%. CONCLUSIONS: The secondary hip fracture rate increased 
with the age of patients. The secondary hip fracture rate was the highest in female, in 
patient with primary intracapsular femoral neck fracture, after arthroplasty, in patient 
with local complication, in patient with capital residence. Many other factors can 
inﬂ uence this secondary hip fractur, which will be analyzed in our further studies.
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OBJECTIVES: The primary aim of this study was to assess the incidence of hip 
fractures in Belgium between 2000 and 2007 and to examine secular changes within 
this period. a secondary aim was to estimate the expected number of hip fractures in 
Belgium until 2050. METHODS: The incidence of hip fractures was determined using 
the national database of hospital bills, which fully cover the annual hospital stays in 
the whole of the country. Population data and projections were derived from ofﬁ cial 
sources. Logistic regression including year and age classes was performed for both 
